Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

National Survey of Patient Factors Associated with Colorectal Cancer Screening Preferences

National Survey of Patient Factors Associated with Colorectal Cancer Screening Preferences Published OnlineFirst April 22, 2021; DOI: 10.1158/1940-6207.CAPR-20-0524 CANCER PREVENTION RESEARCH | RESEARCH ARTICLE National Survey of Patient Factors Associated with A C Colorectal Cancer Screening Preferences 1 2 2 1 1,3 4 Xuan Zhu , Philip D. Parks , Emily Weiser , Kristin Fischer , Joan M. Griffin , Paul J. Limburg , 1,3 and Lila J. Finney Rutten ABSTRACT Recommended colorectal cancer screening modalities 1.22–5.65 and OR, 2.73; 95% CI, 1.13–7.47]. People vary with respect to safety, efficacy, and cost. Better under- who had heard of stool-based screening were more likely standing of the factors that influence patient preference is, to prefer mt-sDNA over FIT/gFOBT (OR, 2.07; 95% CI, therefore, critical for improving population adherence to 1.26–3.40). People who previously had a stool-based colorectal cancer screening. To address this knowledge gap, test were more likely to prefer FIT/gFOBT over colonos- we conducted a panel survey focused on three commonly copy (OR, 2.75; 95% CI, 1.74–4.41), while people utilized colorectal cancer screening options [fecal immuno- who previously had a colonoscopy were less likely to chemical test or guaiac-based fecal occult blood test prefer mt-sDNA or FIT/gFOBT over colonoscopy (OR, (FIT/gFOBT), multi-target stool DNA (mt-sDNA) test, and 0.39; 95% CI, http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Cancer Prevention Research American Association of Cancer Research

National Survey of Patient Factors Associated with Colorectal Cancer Screening Preferences

National Survey of Patient Factors Associated with Colorectal Cancer Screening Preferences

Cancer Prevention Research , Volume 14 (5) – May 1, 2021

Abstract

Published OnlineFirst April 22, 2021; DOI: 10.1158/1940-6207.CAPR-20-0524 CANCER PREVENTION RESEARCH | RESEARCH ARTICLE National Survey of Patient Factors Associated with A C Colorectal Cancer Screening Preferences 1 2 2 1 1,3 4 Xuan Zhu , Philip D. Parks , Emily Weiser , Kristin Fischer , Joan M. Griffin , Paul J. Limburg , 1,3 and Lila J. Finney Rutten ABSTRACT Recommended colorectal cancer screening modalities 1.22–5.65 and OR, 2.73; 95% CI, 1.13–7.47]. People vary with respect to safety, efficacy, and cost. Better under- who had heard of stool-based screening were more likely standing of the factors that influence patient preference is, to prefer mt-sDNA over FIT/gFOBT (OR, 2.07; 95% CI, therefore, critical for improving population adherence to 1.26–3.40). People who previously had a stool-based colorectal cancer screening. To address this knowledge gap, test were more likely to prefer FIT/gFOBT over colonos- we conducted a panel survey focused on three commonly copy (OR, 2.75; 95% CI, 1.74–4.41), while people utilized colorectal cancer screening options [fecal immuno- who previously had a colonoscopy were less likely to chemical test or guaiac-based fecal occult blood test prefer mt-sDNA or FIT/gFOBT over colonoscopy (OR, (FIT/gFOBT), multi-target stool DNA (mt-sDNA) test, and 0.39; 95% CI,

Loading next page...
 
/lp/american-association-of-cancer-research/national-survey-of-patient-factors-associated-with-colorectal-cancer-qfqUBjQWWz

References (48)

Publisher
American Association of Cancer Research
Copyright
©2021 American Association for Cancer Research.
ISSN
1940-6207
eISSN
1940-6215
DOI
10.1158/1940-6207.capr-20-0524
Publisher site
See Article on Publisher Site

Abstract

Published OnlineFirst April 22, 2021; DOI: 10.1158/1940-6207.CAPR-20-0524 CANCER PREVENTION RESEARCH | RESEARCH ARTICLE National Survey of Patient Factors Associated with A C Colorectal Cancer Screening Preferences 1 2 2 1 1,3 4 Xuan Zhu , Philip D. Parks , Emily Weiser , Kristin Fischer , Joan M. Griffin , Paul J. Limburg , 1,3 and Lila J. Finney Rutten ABSTRACT Recommended colorectal cancer screening modalities 1.22–5.65 and OR, 2.73; 95% CI, 1.13–7.47]. People vary with respect to safety, efficacy, and cost. Better under- who had heard of stool-based screening were more likely standing of the factors that influence patient preference is, to prefer mt-sDNA over FIT/gFOBT (OR, 2.07; 95% CI, therefore, critical for improving population adherence to 1.26–3.40). People who previously had a stool-based colorectal cancer screening. To address this knowledge gap, test were more likely to prefer FIT/gFOBT over colonos- we conducted a panel survey focused on three commonly copy (OR, 2.75; 95% CI, 1.74–4.41), while people utilized colorectal cancer screening options [fecal immuno- who previously had a colonoscopy were less likely to chemical test or guaiac-based fecal occult blood test prefer mt-sDNA or FIT/gFOBT over colonoscopy (OR, (FIT/gFOBT), multi-target stool DNA (mt-sDNA) test, and 0.39; 95% CI,

Journal

Cancer Prevention ResearchAmerican Association of Cancer Research

Published: May 1, 2021

There are no references for this article.